Clinical trials: Relapsing Multiple Sclerosis
Multiple Sclerosis (MS) - Relapsing-remitting
Synbiotic Supplementation as a Part of Dietary Modification in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system, influenced by genetic, epigenetic, and immunological factors, as well as environmental factors such as nutrition.
- Trial name
- Synbiotic-MS (NCT07789171)
- Testing
- MNT+Synbiotic
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Hacettepe University
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple…
- Trial name
- NCT06846281
- Testing
- Remibrutinib oral treatment, Ocrelizumab
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05147220
- Testing
- Remibrutinib, Teriflunomide
- Where
- 200 sites in United States, Argentina and 32 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- DanNORMS (NCT04688788)
- Testing
- Rituximab, Ocrelizumab, Fexofenadine
- Where
- 11 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of Tysabri on cognitive fatigue in persons with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT04565431
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis (MS) Relapsing Remitting
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)
The investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- Trial name
- NCT07757568
- Testing
- Vumerity, Tecfidera
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS) - Relapsing-remitting
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial.
- Trial name
- REDIFINE MS (NCT07758270)
- Testing
- Remibrutinib, Ocrelizumab (US)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Relapsing Multiple Sclerosis (RMS)
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing…
- Trial name
- FILIOS (NCT06869785)
- Testing
- Ofatumumab approved dose, Ofatumumab new dose
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 196 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
This study is a randomized controlled trial (RCT) that compares the effects of two different 12-month aerobic walking exercise programs on cognitive processing speed (CPS), brain MRI, and other functional outcomes in 32 adults…
- Trial name
- NCT05755061
- Testing
- GEMS Plus, GEMS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently.
- Trial name
- CoQualSEP (NCT01392872)
- Testing
- Neuropsychological assessment
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.
Relapsing Multiple Sclerosis
Characterizing the Use of Ofatumumab in a Real World Setting
This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact…
- Trial name
- EAFToS (NCT05090033)
- Testing
- ofatumumab
- Where
- 7 sites in Australia
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) - Relapsing-remitting, Mediterranean Diet
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HistaMed-MS (NCT07501520)
- Testing
- Low Histamine-Based Modified Mediterranean Diet, Traditional Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Firat University